Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts [Yahoo! Finance]
Inhibrx, Inc. (INBX)
Company Research
Source: Yahoo! Finance
a comprehensive progress update regarding its primary oncology programs. The company is currently advancing two lead therapeutic candidates: INBRX-106, which is a hexavalent sdAb-based OX40 agonist, and ozekibart (INBRX-109), which is a tetravalent death receptor 5 (DR5) agonist. These candidates use precise protein engineering to optimize immune system activation and tumor-targeted cell death. The INBRX-106 program is centered on a Phase 2/3 clinical trial evaluating the drug in combination with Keytruda (pembrolizumab) as a first-line treatment for locally advanced unresectable or metastatic head and neck squamous cell carcinoma/HNSCC. As of December, Inhibrx recruited 46 out of the 60 patients required for the randomized Phase 2 portion of this study. The trial enrolls patients who have not received prior systemic therapy and exhibit a tumor PD-L1 CPS expression of 20 or greater. Enrollment for this Phase 2 portion is expected to be completed in Q1 2026. Simultaneously, the com
Show less
Read more
Impact Snapshot
Event Time:
INBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INBX alerts
High impacting Inhibrx, Inc. news events
Weekly update
A roundup of the hottest topics
INBX
News
- Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program [Yahoo! Finance]Yahoo! Finance
- Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) ProgramPR Newswire
- Best Quant-rated small- and mid-cap healthcare stocks as LLY hits $1T in market cap [Seeking Alpha]Seeking Alpha
- Inhibrx Biosciences (NASDAQ:INBX) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Inhibrx Biosciences GAAP EPS of -$2.28 [Seeking Alpha]Seeking Alpha
INBX
Earnings
- 8/13/25 - Beat
INBX
Analyst Actions
- 11/19/25 - Citigroup Inc.
INBX
Sec Filings
- 12/16/25 - Form 8-K
- 11/14/25 - Form 10-Q
- 11/14/25 - Form 8-K
- INBX's page on the SEC website